Skip to main content

Table 2 Anthropometry, biochemical and inflammatory variables in different moments of the study protocol.

From: Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

 

Baseline

Monotherapy

Combination

p value

Ezetimibe group

    

Body mass index (kg/m2)

33.0 ± 0.9

32.4 ± 0.9*

32.4 ± 1.0*

0.002

Abdominal circumference (cm)

102.9 ± 2.1

100.6 ± 2.2*

101.4 ± 2.2

0.010

Total cholesterol (mg/dL)

237.4 ± 8.8

197.0 ± 7.2*

147.8 ± 6.4*#

<0.001

LDL-cholesterol (mg/dL)

145.9 ± 8.2

112.5 ± 6.4*

66.6 ± 4.8*#

<0.001

HDL-cholesterol (mg/dL)

56.1 ± 2.8

55.4 ± 2.1

56.9 ± 2.5

0.855

Triglycerides (mg/dL)

176.8 ± 17.4

145.4 ± 15.9*

121.4 ± 11.3*

<0.001

Apolipoprotein B (mg/dL)

115.6 ± 5.0

93.3 ± 4.6*

66.9 ± 3.7*#

<0.001

Apolipoprotein A-I (mg/dL)

157.7 ± 5.3

153.2 ± 5.0

151.1 ± 6.3

0.149

Leucocytes (×103 cel/mm3)

5.83 ± 0.26

6.07 ± 0.25

6.00 ± 0.31

0.394

C reactive protein (mg/dL)

0.57 ± 0.12

0.46 ± 0.09

0.44 ± 0.14

0.452

Interleukin-6 (pg/mL)

3.1 ± 0.5

2.5 ± 0.3

2.5 ± 0.2

0.286

TNF-α (pg/mL)

8.8 ± 3.2

5.9 ± 0.3

6.1 ± 0.2

0.229

Simvastatin group

    

Body mass index (kg/m2)

31.9 ± 0.7

31.8 ± 0.7

31.6 ± 0.8

0.660

Abdominal circumference (cm)

101.8 ± 1.6

101.8 ± 1.6

101.3 ± 1.9

0.999

Total cholesterol (mg/dL)

214.4 ± 7.9

168.1 ± 8.3*

139.5 ± 7.0*#

<0.001

LDL-cholesterol (mg/dL)

129.4 ± 7.4

84.8 ± 7.0*

62.4 ± 5.5*#

<0.001

HDL-cholesterol (mg/dL)

53.1 ± 2.3

53.2 ± 2.4

54.5 ± 2.5

0.885

Triglycerides (mg/dL)

160.0 ± 13.1

150.5 ± 17.3

112.6 ± 9.7*#

<0.001

Apolipoprotein B (mg/dL)

103.8 ± 4.8

77.9 ± 4.5*

63.3 ± 4.0*#

<0.001

Apolipoprotein A-I (mg/dL)

154.9 ± 3.8

152.1 ± 4.2

152.5 ± 4.7

0.375

Leucocytes (×103 cel/mm3)

5.91 ± 0.36

5.87 ± 0.40

5.91 ± 0.44

0.924

C reactive protein (mg/dL)

0.59 ± 0.14

0.48 ± 0.12

0.35 ± 0.12*#

0.023

Interleukin-6 (pg/mL)

2.8 ± 0.3

2.3 ± 0.2

2.5 ± 0.2

0.146

TNF-α (pg/mL)

6.1 ± 0.2

6.2 ± 0.2

6.6 ± 0.4

0.261

  1. Data are expressed in means ± standard error.
  2. * p < 0.017 versus baseline
  3. # p < 0.017 versus monotherapy
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us